ANDEXXA: The First and Only FDA-approved Agent for Reversal of FXa Inhibitor Activity in Patients With Life-threatening or Uncontrolled Bleeding
Tuesday, August 2nd, 2022 | 11:00 AM - 12:00 PM CT
This program will discuss the burden of life-threatening bleeds related to FXa inhibitors, and focus on the mechanism of action, efficacy, and safety of a reversal agent indicated for patients treated with anticoagulants who have life-threatening bleeding.
- The Burden of Life-threatening Bleeds Related to FXa Inhibitors
- Mechanistic Rationale for the Reversal of Anti-FXa Activity
- Clinical Trials Evaluating the Efficacy and Safety of ANDEXXA in the Reversal of Apixaban or Rivaroxaban
- The Real-world Use of ANDEXXA In the Reversal of Apixaban or Rivaroxaban